Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia.
Tefferi
Ayalew
A
Levitt
Ralph
R
Lasho
Terra L
TL
Knudson
Ryan A
RA
Ketterling
Rhett P
RP
D000368:Aged; D019943:Amino Acid Substitution; D000970:Antineoplastic Agents / Q000009:adverse effects; D001549:Benzamides; D016313:Genes, abl; D006801:Humans; D000068877:Imatinib Mesylate; D053614:Janus Kinase 2 / Q000235:genetics*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D008297:Male; D020125:Mutation, Missense; D010879:Piperazines / Q000009:adverse effects*; D011087:Polycythemia Vera / Q000201:enzymology / Q000209:etiology* / Q000235:genetics; D011743:Pyrimidines / Q000009:adverse effects*; D013997:Time Factors
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C507924:JAK2 protein, human; D053614:Janus Kinase 2